RNAZ insider filings
Transcode Therapeutics, Inc. — 33 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-21. Screen RNAZ transaction legs live →
Insider transaction summary — last 90 days
2026-07-26 to 2026-10-24, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| DEFJ, LLC — 10% owner & CK Life Sciences Intl (Holdings) Inc — 10% owner | 1 | — | — | 4 |
| Fitzgerald Thomas A — Chief Financial Officer, Director | 1 | — | — | 1 |
| Tattory John A — Interim CFO | 1 | — | — | — |
Recent insider filings — Transcode Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-21 | 3 | Tattory John A — Interim CFO | Holdings only — no transactions reported | EDGAR |
| 2026-09-11 | 4 | Fitzgerald Thomas A — Chief Financial Officer, Director | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | DEFJ, LLC — 10% owner CK Life Sciences Intl (Holdings) Inc — 10% owner | Conversion (C): 11,813,859 · Conversion (C): 2,020,582 · Conversion (C): 1,181.39 (derivative) @ $0 · Conversion (C): 202.06 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Manting Erik — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Fitzgerald Thomas A — Interim CEO, CFO, Director | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Calais Philippe — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Marquet Magda — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2023-10-02 | 4 | Fitzgerald Thomas A — Chief Financial Officer, Director | Purchase (P): 49,350 @ $0.51 | EDGAR |
| 2023-10-02 | 4 | Dudley Robert Michael — Chief Executive Officer, Director | Purchase (P): 98,000 @ $0.51 | EDGAR |
| 2023-06-22 | 4 | Dudley Robert Michael — Chief Executive Officer, Director | Purchase (P): 6,607 @ $2.55 · Purchase (P): 12,000 @ $2.65 | EDGAR |
| 2023-06-14 | 4/A | Dudley Robert Michael — Chief Executive Officer, Director | Purchase (P): 19,000 @ $2.76 | EDGAR |
| 2023-06-13 | 4 | Dudley Robert Michael — Chief Executive Officer, Director | Purchase (P): 19,000 @ $2.76 | EDGAR |
| 2023-05-19 | 4 | Manting Erik — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Fitzgerald Thomas A — Chief Financial Officer, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Dudley Robert Michael — Chief Executive Officer, Director | Grant/award (A): 735,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Calais Philippe — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Marquet Magda — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-05-10 | 4 | Manting Erik — Director | Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
| 2023-05-10 | 4 | Calais Philippe — Director | Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
| 2023-05-10 | 4 | Marquet Magda — Director | Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
| 2022-12-14 | 4 | Fitzgerald Thomas A — Chief Financial Officer, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-12-14 | 4 | Dudley Robert Michael — Chief Executive Officer, Director, 10% owner | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2022-12-14 | 4 | Medarova Zdravka — Chief Technology Officer, 10% owner | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2022-12-14 | 4 | Medarova Zdravka — Chief Technology Officer, 10% owner | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2022-09-16 | 4 | Dudley Robert Michael — Chief Executive Officer, Director, 10% owner | Purchase (P): 20,000 @ $1.15 | EDGAR |
| 2022-06-22 | 4 | Manting Erik — Director | Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Calais Philippe — Director | Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Marquet Magda — Director | Grant/award (A): 9,500 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Fitzgerald Thomas A — Chief Financial Officer, Director | Purchase (P): 12,000 @ $1.27 | EDGAR |
| 2022-06-01 | 4 | Dudley Robert Michael — Chief Executive Officer, Director, 10% owner | Purchase (P): 28,000 @ $1.84 · Purchase (P): 2,000 @ $1.87 | EDGAR |
| 2022-03-02 | 4 | Fitzgerald Thomas A — Chief Financial Officer, Director | Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
| 2022-02-03 | 4 | Fitzgerald Thomas A — Chief Financial Officer, Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2022-02-03 | 4 | Dudley Robert Michael — Chief Executive Officer, Director, 10% owner | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Transcode Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | EDGAR |
| 2026-09-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-17 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-18 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | ? | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RNAZ returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs